Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]
In development
Reference number: GID-TA10620
Expected publication date:
Following an update from the company the timelines for this appraisal are to be confirmed. Further information regarding the scheduling of the appraisal will be available in due course.